Current $75 is 29% above DCF FV $58. P(above)=11.3% — model gives 89% odds of underperformance. Diagnostics -1.3% (COVID normalization), Brevera recall headwind, tariff drag. GYN Surgical +8.7% is positive. Merger backstop ($79) was the bull case but standalone fundamentals dont support current valuation. Cannot justify 6 when stock is structurally above FV with DCF disagreement.
Fair Value Distribution — percentile bands
9.4% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
6.3%/yr
±4.9% · revenue growth to justify current price
FCF-Based Reverse DCF
1.7%/yr
±2.9% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~7h).
Eagle will generate this view by the next trading session (~7h).
Q1 FY26 revenues flat-ish (+2.5% YoY) at ,047.8M. Diagnostics down 1.3% (COVID normalization, assay pressures). Breast Health +1.8% but headwind from Brevera 9G needle stop-ship (4.7% of segment). GYN...